トピック一覧へ
Year 3 · Subject
Pharmacology
149 notes
01A1A1: Cholinergic and adrenergic transmission and its presynaptic modificationコリン作動性・アドレナリン作動性伝達とそのシナプス前調節02A2A2: Cholinomimeticsコリン作動薬03A3A3: Muscarinic receptor blocking drugsムスカリン受容体遮断薬04A4A4: Catecholaminesカテコールアミン05A5A5: Indirect sympathomimetics. Selective α1 agonists間接型交感神経刺激薬・選択的α1作動薬06A6A6: α2-agonists and drugs acting on the imidazoline receptorsα2作動薬およびイミダゾリン受容体作用薬07A7A7: α-receptor antagonistsα受容体拮抗薬08A8A8: β-receptor antagonistsβ受容体拮抗薬09A9A9: Centrally and peripherally acting skeletal muscle relaxants中枢性・末梢性骨格筋弛緩薬10A10A10: Local anesthetics局所麻酔薬11A11A11: Opioidsオピオイド12A12A12: NSAIDs非ステロイド性抗炎症薬(NSAIDs)13A13A13: Drugs used for treatment of gout. Drugs for headache syndromes痛風治療薬・頭痛治療薬14A14A14: Inhalational anesthetics吸入麻酔薬15A15A15: Intravenous anesthetics. Perioperative medication静脈麻酔薬・周術期薬剤16A16A16: Benzodiazepinesベンゾジアゼピン17A17A17: Non-benzodiazepine anxiolytics and non-benzodiazepine hypnotics非ベンゾジアゼピン系抗不安薬・睡眠薬18A18A18: Antipsychotics抗精神病薬19A19A19: Monoamine reuptake inhibitorsモノアミン再取り込み阻害薬20A20A20: Non-reuptake-inhibitor antidepressants. Agents used for treatment of manic phase of bipolar disorders非再取り込み阻害型抗うつ薬・双極性障害躁状態治療薬21A21A21: Antiepileptics. Adjuvant analgesics抗てんかん薬・鎮痛補助薬22A22A22: Drugs of neurodegenerative diseases (extrapyramidal motoric system, nootropic drugs)神経変性疾患治療薬(錐体外路系・脳代謝賦活薬)23B1B1: Drugs influencing blood coagulation I: Antiplatelet agents. Fibrinolytic drugs. Drugs inhibiting bleeding血液凝固に作用する薬I：抗血小板薬・線溶薬・止血薬24B2B2: Drugs influencing blood coagulation II: Anticoagulant drugs血液凝固に作用する薬II：抗凝固薬25B3B3: Agents used in anemias貧血治療薬26B4B4: Positive inotropic drugs強心薬(陽性変力薬)27B5B5: Drugs influencing cardiac electrophysiology心臓電気生理に作用する薬(抗不整脈薬)28B6B6: Drugs acting on the renin-angiotensin-aldosterone-system (RAAS)レニン・アンジオテンシン・アルドステロン系(RAAS)作用薬29B7B7: Ca++-channel blockers and other vasodilatorsカルシウム拮抗薬およびその他の血管拡張薬30B8B8: Drugs influencing the oxygen demand and oxygen supply of the heart. Drugs improving microcirculation心臓の酸素需要・供給に作用する薬・微小循環改善薬31B9B9: Drugs affecting lipid metabolism. Drugs controlling body weight脂質代謝に作用する薬・体重管理薬32B10B10: Potassium excreting (wasting) diureticsカリウム排泄性利尿薬33B11B11: Potassium sparing diuretics, ADH antagonists, osmotic diureticsカリウム保持性利尿薬・ADH拮抗薬・渗透圧利尿薬34B12B12: Glucocorticoids for oral and parenteral use経口・非経口グルココルチコイド35B13B13: Mineralocorticoids. Topically applied glucocorticoids. Adrenocortical antagonists, inhibitors of corticosteroid synthesisミネラルコルチコイド・外用グルココルチコイド・副腎皮質拮抗薬及びステロイド合成阻害薬36B14B14: Androgens, anabolic steroids, antiandrogens. Agents affecting the sexual activityアンドロゲン・蛋白同化ステロイド・抗アンドロゲン薬・性機能作用薬37B15B15: Estrogens and antiestrogensエストロゲンおよび抗エストロゲン薬38B16B16: Progestins and antiprogestins. Contraceptivesプロゲスチン・抗プロゲスチン薬・避妊薬39B17B17: Thyroid and antithyroid drugs. Pituitary hormones. Hypothalamic hormones, hormonanalogs and antagonists甲状腺・抗甲状腺薬・下垂体ホルモン・視床下部ホルモン及びその類似体・拮抗薬40B18B18: Pancreatic hormones and parenterally applied antidiabetic drugs膵ホルモンおよび注射用抗糖尿病薬41B19B19: Oral antidiabetics経口血糖降下薬42B20B20: Agents affecting bone mineral homeostasis (calcium, vitamin D, parathyroid hormone, calcitonin, etc.)骨ミネラル恒常性に作用する薬(カルシウム・ビタミンD・副甲状腺ホルモン・カルシトニンなど)43B21B21: Selective β2-stimulants and other bronchodilators選択的β2刺激薬およびその他の気管支拡張薬44B22B22: Antiinflammatory agents inhibiting bronchial inflammatory processes. Antitussive agents and expectorants気管支抗炎症薬・鎮咳薬・去痰薬45B23B23: Drugs influencing gastric acid secretion, protective drugs of gastric mucosa胃酸分泌に作用する薬・胃粘膜保護薬46B24B24: Antiemetic drugs. Prokinetic agents制吐薬・消化管運動促進薬47B25B25: Drugs used in constipation (laxatives) and diarrhea. Drugs promoting digestion. Pharmacology of liver and biliary tract便秘薬(下剤)・止瀉薬・消化促進薬・肝胆道系薬理48B26B26: Histamine and antihistaminesヒスタミンおよび抗ヒスタミン薬49B27B27: Drugs acting on smooth muscles. Drugs influencing uterus contractions平滑筋作用薬・子宮収縮作用薬50B28B28: Immunopharmacology I (cytotoxic agents)免疫薬理学I(細胞傷害性薬)51B29B29: Immunopharmacology II (Inhibitors of cytokine gene expression, 5-ASA derivatives)免疫薬理学II(サイトカイン遺伝子発現阻害薬・5-ASA誘導体)52B30B30: Immunopharmacology III (Antibodies and fusion proteins)免疫薬理学III(抗体・融合タンパク質)53B31B31: Drugs used in cancer treatment I (antimetabolites)抗がん薬I(代謝拮抗薬)54B32B32: Drugs used in cancer treatment II (cytotoxic agents targeting DNA)抗がん薬II(DNA標的細胞傷害性薬)55B33B33: Drugs used in cancer treatment III (Topoisomerase inhibitors. Inhibitors of mitotic spindle)抗がん薬III(トポイソメラーゼ阻害薬・紡錘体阻害薬)56B34B34: Drugs used in cancer treatment IV (Hormonal agents)抗がん薬IV(ホルモン薬)57B35B35: Drugs used in cancer treatment V (Small molecule signal transduction inhibitors. Retinoids)抗がん薬V(低分子シグナル伝達阻害薬・レチノイド)58B36B36: Drugs used in cancer treatment VI (Large molecule signal transduction inhibitors. Immunostimulant anticancer drugs)抗がん薬VI(高分子シグナル伝達阻害薬・免疫賦活抗がん薬)59C1C1: Disinfectants and antiseptics消毒薬・防腐薬60C2C2: Antimycobacterial drugs抗抗酸菌薬(抗結核薬)61C3C3: Antiprotozoal and antihelminthic drugs抗原虫薬・駆虫薬62C4C4: Antifungal agents抗真菌薬63C5C5: Agents to treat Herpes simplex (HSV), varicella-zoster (VZV), cytomegalovirus (CMV). Anti-influenza agents. Drugs against Corona- and other viruses抗ヘルペス・抗水痘帯状疱疹・抗サイトメガロウイルス薬・抗インフルエンザ薬・抗コロナその他ウイルス薬64C6C6: Antiretroviral agents抗レトロウイルス薬65C7C7: Agents against hepatitis viruses抗肝炎ウイルス薬66C8C8: Penicillinsペニシリン系67C9C9: Cephalosporinsセファロスポリン系68C10C10: Carbapenems. Monobactams. Beta-lactamase inhibitorsカルバペネム系・モノバクタム系・βラクタマーゼ阻害薬69C11C11: Chloramphenicol. Polymyxins. Antifolate drugsクロラムフェニコール・ポリミキシン・葉酸拮抗薬70C12C12: Tetracyclines and glycylcyclinesテトラサイクリン系・グリシルサイクリン系71C13C13: Aminoglycosidesアミノグリコシド系72C14C14: Quinolones and fluoroquinolonesキノロン系・フルオロキノロン系73C15C15: Macrolides. Pleuromutilinsマクロライド系・プレウロムチリン系74C16C16: Clindamycin. Streptogramins. Oxazolidinones. Fusidansクリンダマイシン・ストレプトグラミン・オキサゾリジノン・フシジン酸系75C17C17: Glycopeptides. Lipopeptides. Bacitracin. Mupirocinグリコペプチド・リポペプチド・バシトラシン・ムピロシン76C18C18: Metronidazole. Fidaxomicin. Rifaximin. Nitrofurantoin. Fosfomycinメトロニダゾール・フィダキソマイシン・リファキシミン・ニトロフラントイン・ホスホマイシン77Core1Core1: Stages of drug development in brief薬物開発の段階(概要)78Core2Core2: Types of clinical trials臨床試験の種類79Core3Core3: History of the Hungarian pharmaceutical industryハンガリー製薬産業の歴史80Core4Core4: Molecular targets of drugs薬物の分子標的81Core5Core5: Receptor theory - agonist, partial agonist, antagonist, inverse agonist受容体理論：作動薬・部分作動薬・拮抗薬・逆作動薬82Core6Core6: Efficacy, potency有効性(効力)と力価83Core7Core7: Dose-effect relationships at population level集団レベルでの用量反応関係84Core8Core8: Adverse drug reactions薬物有害反応85Core9Core9: Therapeutic index治療係数86Core10Core10: Tolerance, tachyphylaxis, dependence耐性・タキフィラキシー・依存87Core11Core11: Absorption of drugs薬物の吸収88Core12Core12: Membrane transport mechanisms膜輸送機構89Core13Core13: Distribution of drugs薬物の分布90Core14Core14: Bioavailabilityバイオアベイラビリティ(生物学的利用能)91Core15Core15: Volume of distribution分布容積92Core16Core16: Phases of drug biotransformation薬物代謝(生体内変換)の相93Core17Core17: Excretion of drugs薬物の排泄94Core18Core18: Linear and non-linear pharmacokinetics線形・非線形薬物動態95Core19Core19: Clearanceクリアランス96Core20Core20: Half-life半減期97Core21Core21: Saturating and maintenance dose飽和用量と維持用量98Core22Core22: Drug accumulation and cumulation薬物の蓄積と累積99Core23Core23: Enzyme inducers酵素誘導薬100Core24Core24: Enzyme inhibitors酵素阻害薬101Core25Core25: Pharmacodynamic interactions - synergism薬力学的相互作用：相乗作用102Core26Core26: Pharmacodynamic interactions - antagonism薬力学的相互作用：拮抗作用103Core27Core27: Pharmacokinetic drug interactions - at the level of absorption薬物動態学的相互作用：吸収レベル104Core28Core28: Pharmacokinetic drug interactions - at the level of distribution薬物動態学的相互作用：分布レベル105Core29Core29: Pharmacokinetic drug interactions - at the level of metabolism薬物動態学的相互作用：代謝レベル106Core30Core30: Pharmacokinetic drug interactions - at the level of elimination薬物動態学的相互作用：排泄レベル107Core31Core31: Special groups - drug interactions: pregnancy特殊集団-薬物相互作用：妊娠108Core32Core32: Special groups - drug interactions: childhood特殊集団-薬物相互作用：小児109Core33Core33: Special groups - drug interactions: ageing特殊集団-薬物相互作用：加齢110Core34Core34: Characterisation of biological medicinal products生物学的医薬品の特性111Core35Core35: Orphan drugsオーファンドラッグ(希少疾病用医薬品)112Core36Core36: Advanced therapy medicinal products. Vaccines先端治療医薬品・ワクチン113Core37Core37: Nutritional supplements栄養補助食品(サプリメント)114Core38Core38: Traditional herbal active substances伝統的生薬有効成分115Core39Core39: Medical device医療機器116Core40Core40: Principles of antimicrobial treatment - selective toxicity抗菌薬治療の原則：選択毒性117Core41Core41: Principles of antimicrobial treatment - empirical, targeted and prophylactic therapy抗菌薬治療の原則：経験的・標的・予防的治療118Core42Core42: Principles of antimicrobial treatment - bactericidal, bacteriostatic antibiotics and antibiotic combinations抗菌薬治療の原則：殺菌性・静菌性抗菌薬と抗菌薬併用119Core43Core43: Principles of antimicrobial treatment - time-, concentration- and exposure-dependent antibiotics抗菌薬治療の原則：時間・濃度・曝露依存性抗菌薬120Core44Core44: Narrow and broad spectrum antibiotics狭域・広域抗菌薬121Core45Core45: Antibiotic selection considerations - pregnancy, childhood抗菌薬選択の考慮事項：妊娠・小児122Core46Core46: Antibiotic selection considerations - infections affecting specific compartments抗菌薬選択の考慮事項：特定部位の感染症123Core47Core47: Considerations for antibiotic choice - comorbidities抗菌薬選択の考慮事項：併存疾患124Core48Core48: Antidote - definition and examples解毒薬：定義と例125Core49Core49: Pharmacogenetics, pharmacogenomics - definition, examples薬理遺伝学・薬理ゲノム学：定義と例126Core50Core50: Classification of drugs according to chemical structure and complexity化学構造と複雑さによる薬物分類127Core51Core51: Drug-induced adverse reaction: sulfonamide allergy and its characterization薬剤性有害反応：スルホンアミドアレルギーとその特徴128Core52Core52: Drug-induced adverse reaction: serotonin syndrome薬剤性有害反応：セロトニン症候群129Core53Core53: Drug-induced adverse reaction: neuroleptic malignant syndrome薬剤性有害反応：悪性症候群130Core54Core54: Drug-induced adverse reaction: Stevens-Johnson syndrome薬剤性有害反応：スティーブンス・ジョンソン症候群131Core55Core55: Drug-induced adverse reaction: pseudomembranous colitis薬剤性有害反応：偽膜性大腸炎132Core56Core56: Drug-induced adverse reaction: cheese reaction薬剤性有害反応：チーズ反応133Core57Core57: Drug-induced adverse reaction: orthostatic hypotension薬剤性有害反応：起立性低血圧134Core58Core58: Drug-induced adverse reaction: hemorrhage薬剤性有害反応：出血135Core59Core59: Drug-induced adverse reaction: thrombosis薬剤性有害反応：血栓症136Core60Core60: Drug-induced adverse reaction: bone marrow damage薬剤性有害反応：骨髄障害137Core61Core61: Drug-induced adverse reaction: nephrotoxicity薬剤性有害反応：腎毒性138Core62Core62: Drug-induced adverse reaction: ototoxicity薬剤性有害反応：聴器毒性139Core63Core63: Drug-induced adverse reaction: hepatotoxicity薬剤性有害反応：肝毒性140Core64Core64: Drug-induced adverse reaction: QT prolongation薬剤性有害反応：QT延長141Core65Core65: Drug-induced adverse reaction: bradycardia / AV block薬剤性有害反応：徐脈・房室ブロック142Core66Core66: Drug-induced adverse reaction: constipation, diarrhea, vomiting薬剤性有害反応：便秘・下痢・嘔吐143Core67Core67: Drug-induced adverse reaction: mucosal damage薬剤性有害反応：粘膜障害144Core68Core68: Drug-induced adverse reaction: weight gain/loss薬剤性有害反応：体重増加・減少145Core69Core69: Drug-induced adverse reaction: sedation薬剤性有害反応：鎮静146Core70Core70: Drug-induced adverse reaction: epileptiform seizures薬剤性有害反応：てんかん性発作147Core71Core71: Drug-induced adverse reaction: sexual dysfunction薬剤性有害反応：性機能障害148Core72Core72: Drug-induced adverse reaction: dental and oral cavity adverse reactions薬剤性有害反応：歯・口腔の有害反応149Core73Core73: The Summary of Product Characteristics製品概要(添付文書/SmPC)